Etoricoxib-induced fixed drug eruption: Report of seven cases

• Published in: Contact dermatitis Vol. 84; no. 3; pp. 192 - 195
• Main Authors: Martínez Antón, Maria Dolores, Galán Gimeno, Cristina, Sánchez de Vicente, Javier, Jáuregui Presa, Ignacio, Gamboa Setién, Pedro M
• Format: Report
• Language: English
• Published: 01.03.2021
• ISSN: 1600-0536
• DOI: 10.1111/cod.13659

BACKGROUNDFixed drug eruption (FDE) is a characteristic form of intraepidermal CD8+ T cell-mediated drug reaction, with repeated appearance of isolated or multiple skin lesions in the same location after receiving the offending drug. Non-steroidal anti-inflammatory drugs (NSAID) are the most common cause. Selective inhibitors of inducible cyclooxygenase 2 (COX-2) provoke a lesser degree of allergic or idiosyncratic adverse reactions than conventional NSAID, but they can cause skin reactions of variable severity. OBJECTIVEEtoricoxib has been related to a variety of unusual skin reactions, including several reports of FDE. METHODSWe perfomed epicutaneous test to diagnose patients with suspected etoricoxib fixe drug rash due to clinical features and reproducibility on at least two occasions. RESULTSWe present seven new cases of etoricoxib-induced fixed drug eruption, with a diagnosis based on clinical presentation. This diagnosis was confirmed by an etoricoxib-positive lesional patch test in six cases and by a positive low-dose oral challenge in the other one. Two patients showed negative patch tests with celecoxib (10% in pet.) on the residual lesions, and oral tolerance was confirmed in one. CONCLUSIONTo our knowledge, this is the largest series on FDE induced by etoricoxib reported to date.